UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
The first two paragraphs of the press release
attached hereto as Exhibit 99.1 are hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File
No. 333-229163, 333-248479,
333-263842, 333-271320
and 333-279791) and Form F-3
(File No. 333-238731,
333-292640 and 333-297347),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
On November 4, 2026, CollPlant Biotechnologies
Ltd. issued a press release entitled “CollPlant Announces Proposed Name Change to OptiPhi Computing Reflecting Expansion to Computing
with Light.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Attached hereto and incorporated by reference herein are the following
exhibits:
| 99.1 |
|
Press Release, dated November 4, 2026. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
COLLPLANT BIOTECHNOLOGIES LTD. |
| |
|
|
|
| Date: November 4, 2026 |
By: |
/s/ Eran Rotem |
| |
|
Name: |
Eran Rotem |
| |
|
Title: |
Chief Executive Officer and
Chief Financial Officer |
Exhibit 99.1
CollPlant Announces Proposed Name Change to
OptiPhi Computing Reflecting Expansion to Computing with Light
Proposed new identity reflects the Company’s
strategic business expansion following its acquisition of LightSolver; change subject to shareholder approval
Rehovot, Israel, November 4, 2026 -- CollPlant
Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its Board of Directors has approved a proposal to change the Company’s
name to OptiPhi Computing Ltd., subject to shareholders approval and completion of the applicable corporate and regulatory procedures.
The proposed name reflects the Company’s focus on computing with light following its acquisition of LightSolver Ltd. (“LightSolver”)
in September 2026.
The Company intends to submit the proposed name
change for approval at an upcoming general meeting of shareholders, scheduled for November 24, 2026. In connection with the proposed change,
the Company also intends to change its Nasdaq trading symbol from “CLGN” to “OPHI”, subject to Nasdaq confirmation
and completion of the applicable process. Until the changes become effective, the Company will continue to operate under the CollPlant
Biotechnologies Ltd. name and trade on Nasdaq under “CLGN”. The Company plans to announce the effective date of the changes
separately.
The proposed OptiPhi Computing name brings together
optics and physics, reflecting the scientific foundations of LightSolver’s technology. While light is already used to transmit data
across computing infrastructure, LightSolver is developing a Laser Processing Unit (LPU) that uses interacting lasers to perform computation
itself. The proposed identity is intended to reflect the Company’s expanded business focus and its growing presence in photonic
computing.
“The transition to OptiPhi Computing marks
a pivotal milestone in our corporate evolution, aligning our identity with the immense, high-growth opportunities we see in photonic computing,”
said Eran Rotem, CEO and CFO of CollPlant. “This new name perfectly captures our expanded strategic vision and our commitment to
driving long-term shareholder value through next-generation deep tech.”
“We believe the future of computing will
be built on light. OptiPhi reflects our ambition to pioneer a fundamentally new computing architecture, where photons do more than carry
information — they compute,” said Dr. Ruti Ben Shlomi, Co-Founder and CEO of LightSolver. “This is an important step
in establishing photonic computing as a core part of the company’s identity while we continue advancing the LPU toward commercialization.”
About CollPlant
CollPlant (Nasdaq: CLGN) is an innovative technology
company operating at the intersection of deep-tech photonic computing and advanced biotechnology. Through its subsidiary LightSolver,
CollPlant is advancing the development of proprietary all-optical laser based computing architectures designed to resolve the world’s
most demanding computational bottlenecks across artificial intelligence, aerospace, financial engineering, and high-performance computing.
CollPlant also retains its proprietary plant-derived recombinant human collagen (rhCollagen) and bio-ink assets, for 3D bioprinting of
tissues and organs and medical aesthetics. For more information about CollPlant, visit www.collplant.com.
Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to,
statements regarding the timing of trading under the Company’s proposed new name and ticker symbol and the future prospects, business
plans and growth strategies of the Company. Forward-looking statements can be identified by words such as “anticipate,” “believe,”
“expect,” “intend,” “plan,” “may,” “should,” “could,” “might,”
“seek,” “target,” “will,” “project,” “continue” and similar expressions or
the negative of such terms. These forward-looking statements are based on assumptions and assessments made in light of management’s
experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside
of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated
in forward-looking statements, including, but not limited to, risks associated with integrating LightSolver’s business, operations
and personnel; LightSolver’s ability to achieve anticipated technological and commercial milestones; uncertainties regarding market
acceptance and adoption of LightSolver’s technology; the ability to develop and commercialize LightSolver’s products and technology
successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological
developments; intellectual property risks; the availability of capital; the Company’s ability to maintain compliance with Nasdaq
listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in the
Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent
Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation
to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required
by applicable law.
Investors Contact
Collplant Biotechnologies
investors@lightsolver.com
Media Contact
ARX North American Equities Desk
collplant@arxhq.com
